Clinical trials: Recurrent Head and Neck Carcinoma
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
This phase 2 trial evaluates the benefit of epacadostat plus pembrolizumab in combination to treat patients with gastroesophageal junction or gastric cancer that has spread to other parts of the body and cannot be removed by…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma
- Trial name
- NCT03196232
- Testing
- Epacadostat, Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- George Albert Fisher
Squamous Cell Carcinoma of the Head and Neck
Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
In this clinical trial, the investigators want to know if cabazitaxel is more effective than methotrexate for patients with recurrent or metastatic squamous cell carcinoma of the head and neck in palliative treatment.
- Trial name
- RACATREX (NCT01528163)
- Testing
- Cabazitaxel, Methotrexate
- Where
- 16 sites in Belgium, Luxembourg
- Volunteers
- 101 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Head and Neck Cancer
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005814
- Testing
- cetuximab, cisplatin, radiation therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
This is a Phase I, open-label, dual-cohort clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of intratumoral injection of recombinant human endostatin adenovirus in combination with a PD-1…
- Trial name
- NCT07154108
- Testing
- recombinant human endostatin adenovirus, PD-1 Inhibitor
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Head and Neck Squamous Cell Carcinoma
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma
- Trial name
- NCT00805012
- Testing
- docetaxel+CDDP, docetaxel+S-1
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Seoul National University Hospital
Recurrent Adenoid Cystic Carcinoma of the Salivary Glands, Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
This is a non-randomized, phase II, open label study of dovitinib in patients with progressive, recurrent and/or metastatic adenoid cystic carcinoma (ACC).
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Salivary Glands, Metastatic Adenoid Cystic Carcinoma of the Salivary Glands, Salivary Gland Cancers, ACC
- Trial name
- DOVE (NCT01678105)
- Testing
- Dovitinib
- Where
- 4 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Head Neck Cancer Squamous Cell Metastatic, Head Neck Cancer Squamous Cell Recurrent
Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck
This study is to evaluate disease control rate (DCR) at 8 weeks of BKM120 administered as therapy for patient with recurrent/metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT01527877
- Testing
- BKM120
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Yonsei University
Esophageal Squamous Cell Carcinoma
Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
The aim of this study is to explore whether FOLFOX6 as treatment could improve the time to progression (TTP) and overall survival (OS) of the patient with recurrent or metastatic esophagus.
- Trial name
- NCT01605305
- Testing
- FOLFOX6
- Volunteers
- 60 people
- Sponsor
- Fudan University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
Randomized phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic or recurrent head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00033618
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)
This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least…
- Trial name
- NCT06629597
- Testing
- YL201, Docetaxel, Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Recurrent Head and Neck Cancer, Head and Neck Cancer
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer.
- Conditions
- Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
- Trial name
- NCT03691714
- Testing
- Durvalumab, Cetuximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Cincinnati
ALK Gene Mutation, BRAF Gene Mutation
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell…
- Conditions
- ALK Gene Mutation, BRAF Gene Mutation, EGFR Gene Mutation, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03049618
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Southern California
Squamous Cell Head and Neck Carcinoma
Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC
This is a phase III randomized blind placebo-controlled study, designed to show the superiority of the experimental arm to the control arm.
- Trial name
- ADHERE (NCT03673735)
- Testing
- Durvalumab, radiotherapy, Cisplatin
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Squamous Cell Carcinoma of Head and Neck
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
This is a single arm phase II trial to study the efficacy and safety of a Cdk inhibitor P276-00 in the treatment of squamous cell carcinoma of head and neck.
- Trial name
- MONARCH (NCT00824343)
- Testing
- P276-00
- Where
- 9 sites in India
- Volunteers
- 86 people
- Sponsor
- Piramal Enterprises Limited
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Phase 1b open-label study to evaluate the safety of selected TIL (TBio-4101) delivered after lymphodepleting chemotherapy and followed by intravenous (IV) bolus aldesleukin (IL-2) and pembrolizumab for patients with advanced…
- Trial name
- NCT06236425
- Testing
- TBio-4101, Pembrolizumab, Platinum based chemotherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Head and Neck Cancer
Thalidomide in Treating Patients With Thyroid Cancer
RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have thyroid cancer.
- Trial name
- NCT00026533
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Kenneth Ain
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Oral Cavity Squamous Cell Carcinoma
Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC Patients.
Anti-cancer treatments have been thought to be closely related to their unique genetic alterations. In the past few years, the investigator have used cDNA microarray to delineate the transcriptome profiles of…
- Trial name
- CTC (NCT03917524)
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Chang Gung Memorial Hospital
Head & Neck Squamous Cell Carcinoma
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
phase II, randomized, double-blind, placebo controlled, non pharmacological clinical trial that aims to determine the effect of postbiotics Postbiotix-HLA™ on immuno-related adverse events (irAEs) in patients with…
- Trial name
- POST-BIO (NCT07485296)
- Testing
- Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., Pembolizumab
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Head and Neck Squamous Cell Carcinoma
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the safety, tolerability and efficacy of intratumoral injections with an Epidermal Growth Factor Receptor (EGFR) AntiSense DNA (BB-401) in patients with metastatic/recurrent HNSCC.
- Trial name
- NCT03433027
- Testing
- BB-401
- Where
- 6 sites in Australia, Russia
- Volunteers
- 16 people
- Sponsor
- Benitec Biopharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.